Sensenig Bethany has reported significant stock transactions in a recent filing, following the merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals. This event is noteworthy as it reflects the ongoing consolidation trend within the pharmaceutical industry, where companies are merging to strengthen their market presence and operational capabilities.

According to the SEC filing dated November 4, 2026, Bethany acquired 4,603 restricted stock units and multiple stock options as part of the merger agreement. These transactions were executed on November 2, 2026, the effective date of the merger.

Background

Sensenig Bethany is associated with Supernus, Inc., a company engaged in the pharmaceutical preparations sector. The recent filing indicates that Supernus, which was previously known as Indivior Pharmaceuticals, has undergone a name change following its merger with Indivior. Supernus is now identified under the Central Index Key (CIK) 0001625297 and operates in the pharmaceutical industry.

What the Filing Says

The filing reveals that Bethany, who is a director at Supernus, received 4,603 restricted stock units and various stock options as part of the merger. The filing states, "each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award." This conversion was based on an exchange ratio of 1.5401, which reflects the terms of the merger agreement.

Impact

This update may affect other directors and executives within Supernus as they navigate their own equity compensation following the merger. Additionally, it highlights the strategic decisions made by companies in the pharmaceutical sector as they adapt to changing market conditions and competitive dynamics.

What's Next

The filing does not say what happens next.